Patents by Inventor Angelika Hausser
Angelika Hausser has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230392147Abstract: The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.Type: ApplicationFiled: December 22, 2022Publication date: December 7, 2023Inventors: Monilola OLAYIOYE, Angelika HAUSSER, Lisa PIEPER, Michaela STROTBEK, Till WENGER
-
Patent number: 11549108Abstract: The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.Type: GrantFiled: November 2, 2020Date of Patent: January 10, 2023Assignee: Boehringer Ingelheim International GmbHInventors: Monilola Olayioye, Angelika Hausser, Lisa Pieper, Michaela Strotbek, Till Wenger
-
Publication number: 20220064690Abstract: The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding said RNA, production host cell lines comprising said RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of said RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.Type: ApplicationFiled: November 12, 2021Publication date: March 3, 2022Inventors: Lore FLORIN, Hitto KAUFMANN, Angelika HAUSSER, Monilola OLAYIOYE, Michaela STROTBEK
-
Patent number: 11230725Abstract: The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding the RNA, production host cell lines comprising the RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of the RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of the RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.Type: GrantFiled: October 6, 2017Date of Patent: January 25, 2022Assignee: Boehringer Ingelheim International GmbHInventors: Lore Florin, Hitto Kaufman, Angelika Hausser, Monilola Olayioye, Michaela Strotbek
-
Publication number: 20210123053Abstract: The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.Type: ApplicationFiled: November 2, 2020Publication date: April 29, 2021Inventors: Monilola OLAYIOYE, Angelika HAUSSER, Lisa PIEPER, Michaela STROTBEK, Till WENGER
-
Patent number: 10858653Abstract: The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1 D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.Type: GrantFiled: February 10, 2017Date of Patent: December 8, 2020Assignee: Boehringer Ingelheim International GmbHInventors: Monilola Olayioye, Angelika Hausser, Lisa Pieper, Michaela Strotbek, Till Wenger
-
Publication number: 20200165605Abstract: The invention relates to the field of cell culture technology. It concerns the knockdown, using RNA interference, or gene knockout, of activating transcription factor 6 beta (ATF6B), or the combination of ceramide synthase 2 (CERS2) and TBC1 domain family member 20 (TBC1 D20) proteins, which play central roles in the cellular secretion pathway. This downregulation leads to improved secretion of biopharmaceutically relevant products produced in mammalian cells. The invention specifically relates to mammalian cells having enhanced secretion of a recombinant therapeutic protein compared to a control cell, a method of producing said mammalian cell, a method for the production of a recombinant secreted therapeutic protein and the use of said mammalian cell for increasing the yield of a recombinant secreted therapeutic protein.Type: ApplicationFiled: February 10, 2017Publication date: May 28, 2020Inventors: Monilola Olayioye, Angelika HAUSSER, Lisa PIEPER, Michaela STROTBEK, Till WENGER
-
Publication number: 20180119191Abstract: The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding said RNA, production host cell lines comprising said RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of said RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.Type: ApplicationFiled: October 6, 2017Publication date: May 3, 2018Applicant: Boehringer Ingelheim International GmbHInventors: Lore Florin, Hitto Kaufman, Angelika Hausser, Monilola Olayioye, Michaela Strotbek
-
Publication number: 20150140591Abstract: The invention concerns the field of cell culture technology. It concerns RNA having a specific sequence, expression vectors encoding said RNA, production host cell lines comprising said RNA, and methods of producing recombinant biopharmaceutical products using engineered host cell with altered levels of said RNAs, such as small non-coding RNAs, preferably microRNAs (miRNAs). The invention also relates to engineered host cells with altered levels in one or more of said RNAs. Those cell lines have improved secretion and/or growth characteristics in comparison to control cell lines.Type: ApplicationFiled: June 4, 2013Publication date: May 21, 2015Inventors: Lore Florin, Hitto Kaufman, Angelika Hausser, Monilola Olayioye, Michaela Strotbek
-
Publication number: 20130196430Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: ApplicationFiled: June 12, 2012Publication date: August 1, 2013Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Hitto KAUFMANN, Lore FLORIN, Eric BECKER, Monilola OLAYIOYE, Angelika HAUSSER, Tim FUGMANN
-
Publication number: 20130197196Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: ApplicationFiled: June 12, 2012Publication date: August 1, 2013Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Hitto KAUFMANN, Lore FLORIN, Eric BECKER, Monilola OLAYIOYE, Angelika HAUSSER, Tim FUGMANN
-
Publication number: 20130177919Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: ApplicationFiled: February 29, 2008Publication date: July 11, 2013Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Hitto Kaufmann, Lore Florin, Eric Becker, Monilola Olayioye, Angelika Hausser, Tim Fugmann
-
Patent number: 8221999Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: GrantFiled: February 29, 2008Date of Patent: July 17, 2012Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Hitto Kaufmann, Lore Florin, Eric Becker, Monilola Olayioye, Angelika Hausser, Tim Fugmann
-
Publication number: 20090018099Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: ApplicationFiled: August 1, 2008Publication date: January 15, 2009Inventors: Hitto Kaufmann, Lore Florin, Eric Becker, Monilola Olayioye, Angelika Hausser, Tim Fugmann
-
Publication number: 20080300207Abstract: The invention concerns the field of protein production and cell culture technology. CERT is identified as a novel in vivo PKD substrate. Phosphorylation on serine 132 by PKD decreases the affinity of CERT towards its lipid target phosphatidylinositol 4-phosphate at Golgi membranes and reduces ceramide transfer activity, identifying PKD as a regulator of lipid homeostasis. The present invention shows that CERT in turn is critical for PKD activation and PKD dependent protein cargo transport to the plasma membrane. The interdependence of PKD and CERT is thus a key to the maintenance of Golgi membrane integrity and secretory transport.Type: ApplicationFiled: February 29, 2008Publication date: December 4, 2008Inventors: Hitto Kaufmann, Lore Florin, Eric Becker, Monilola Olayioye, Angelika Hausser, Tim Fugmann